# Safety and Efficacy of Eculizumab in High-risk TA-TMA

> **NCT07707687** · PHASE2 · RECRUITING · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 24 (estimated)

## Conditions studied

- Transplant-Associated Thrombotic Microangiopathy (TA-TMA)

## Interventions

- **DRUG:** Eculizumab

## Key facts

- **NCT ID:** NCT07707687
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-10
- **Primary completion:** 2028-07-10
- **Final completion:** 2028-07-10
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-07-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07707687

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07707687, "Safety and Efficacy of Eculizumab in High-risk TA-TMA". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07707687. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*